Findings

What do systematic reviews say?

469 questions · 483 findings · 63 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 117 · 24.2%GRADE not reported 13 · 2.7%Very low 68 · 14.1%Low 141 · 29.2%Moderate 112 · 23.2%High 32 · 6.6%

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Overall survival (OS) · recurrent EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.92 [0.8, 1.06]
3 studies · 1250 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Progression‐free survival · recurrent EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) leads to lower progression‐free survival (PFS) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.73 [0.65, 0.82]
3 studies · 1250 participants
High

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

QoL · recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 315 participants
Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Hypertension (grade ≥ 2)Â · recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · recurrent EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 0.35 [0.01, 8.3]
1 study · 108 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.99 [0.84, 1.17]
2 studies · 1451 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Progression‐free survival (PSF) · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.88 [0.77, 1]
2 studies · 1451 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1340 participants
Moderate

Third generation cephalosporins vs conventional therapy

Death · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 1496 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Death · patients treated for meningococcal meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 477 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Deafness · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 501 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Culture positivity 10 to 48 hours start of treatment · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 442 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Diarrhoea · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 750 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Neutropenia · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 472 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Rash · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 533 participants
GRADE not reported

Third generation cephalosporins vs conventional therapy

Treatment failure (either death or deafness) · patients treated for acute bacterial meningitis

1 finding from 1 review

Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis 2007 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 1496 participants
GRADE not reported

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.97 [0.88, 1.07]
2 studies · 2776 participants
Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.9 [0.79, 1.02]
3 studies · 1564 participants
Moderate